Accelerating Clinical Trials In The EU

In the past few days the European Commission (EC), Heads of Medicines Agencies (HMA), and the European Medicines Agency (EMA) have launched an initiative to transform how clinical trials are initiated, designed, and run across the union.

Referred to as Accelerating Clinical Trials in the EU (ACT EU), the aim is to further develop the EU as a focal point for clinical research, further promote the development of high quality, safe and effective medicines, and to better integrate clinical research in the European health system.

Building on the application of the Clinical Trials Regulation and the launch of the Clinical Trials Information System (CTIS) we previously posted about which is due to go live on the 31st January, ACT EU aims to strengthen the European environment for clinical trials, whilst maintaining the high level of protection of trial participants, data robustness and transparency that EU citizens expect.

As a starting point the ACT EU strategy paper lists ten priority actions for 2022/2023, including enabling innovative trial methods, establishing a multi-stakeholder platform, and supporting the modernization of good clinical practice, something specialist clinical trial providers such as EU-based QUINTA-ANALYTICA sincerely applaud.

With 25 years of experience in the provision of pharma services across the continent and internationally, Quinta are well-positioned to support trials across any number of testing scenarios from the design of the study all the way through pharmacokinetic and statistical evaluation.  Speak to our team to learn more.

Additional News

  • 18 July 2023

    Challenges of a large-scale study of breast cancer

    Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.

  • 29 June 2023

    EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.

    After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.

  • 22 June 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency